Depression Treatment: Anxiety and Depression in Australian Chronic Hepatitis C Outpatients: Prevalence and Predictors.

Anxiety and depression in Australian chronic hepatitis C outpatients: prevalence and predictors.

Filed under: Depression Treatment

Australas Psychiatry. 2012 Oct 25;
Stewart B, Mikocka-Walus A, Morgan J, Colman A, Phelps M, Harley H, Andrews J

OBJECTIVE: The present study aimed to assess the prevalence and predictors of anxiety and depression in Australian chronic hepatitis C (CHC) outpatients. METHOD: Hospital Anxiety and Depression Scale scores at referral and other patient data was analysed for 395 CHC outpatients attending the Royal Adelaide Hospital liver clinic from 2006 to 2010. RESULTS: Results revealed probable prevalence rates of 41% for anxiety and 27% for depression. CHC patients had rates of anxiety and depression 1.2 and 2.4 times higher than community norms, respectively. Younger patients were found to experience increased anxiety, while married patients or those in a de facto relationship experienced decreased anxiety and depression. CONCLUSION: Regular psychiatric screening, and subsequent referral for mental health treatment, where necessary, is recommended for Australian CHC patients. Younger patients or those lacking social supports may be at increased risk. Research is needed to develop and evaluate psychological interventions.
HubMed – depression

 

Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder.

Filed under: Depression Treatment

Br J Psychiatry. 2012 Oct 25;
Amsterdam JD, Luo L, Shults J

BACKGROUND: Controversy exists over antidepressant use in rapid-cycling bipolar disorder. AIMS: Exploratory analysis of safety and efficacy of fluoxetine v. lithium monotherapy in individuals with rapid- v. non-rapid-cycling bipolar II disorder. METHOD: Randomised, double-blind, placebo-controlled comparison of fluoxetine v. lithium monotherapy in patients initially stabilised on fluoxetine monotherapy (trial registration NCT00044616). RESULTS: The proportion of participants with depressive relapse was similar between the rapid- and non-rapid-cycling groups (P = 0.20). The odds of relapse were similar between groups (P = 0.36). The hazard of relapse was similar between groups (hazard ratio 0.87, 95% CI 0.40-1.91). Change in mania rating scores was similar between groups (P = 0.86). There was no difference between groups in the rate of syndromal (P = 0.27) or subsyndromal (P = 0.82) hypomania. CONCLUSIONS: Depressive relapse and treatment-emergent mood conversion episode rates were similar for lithium and fluoxetine monotherapy and placebo during long-term, relapse-prevention therapy of rapid- and non-rapid-cycling bipolar II disorder.
HubMed – depression

 

Neural Regeneration: Role of Traditional Chinese Medicine in Neurological Diseases Treatment.

Filed under: Depression Treatment

J Pharmacol Sci. 2012 Oct 26;
Ren ZL, Zuo PP

The effects of a single compound and a mixture of traditional Chinese medicine (TCM) on promoting proliferation, differentiation, and migration of neural stem cells and regulating their microenvironment have been observed by Chinese scholars in recent years. These results showed good prospects in improving neural regeneration and repair of neurological disorders such as ischemic brain injury, Alzheimer’s disease, Parkinson’s disease, and depression. According to the TCM theory, the relationship between life of an individual and the disease was regarded as an entirety, and the theory emphasized the treatment based on syndrome differentiation since ancient times. In this paper, we attempted to introduce these medicines, which belong to natural products and have already been proved to possess clear therapeutic action on human bodies in the clinical setting. We summarized their effects promoting brain neurogenesis and repairing brain injuries in animal models and some mechanisms at the cellular and molecular levels.
HubMed – depression

 

depression and its treatment john h greist

$7.00 (0 Bids)
End Date: Monday Sep-23-2019 15:10:53 PDT
Bid now | Add to watch list

 

Treatment of Tricyclic Resistant Depression (Progr
$12.09
End Date: Thursday Oct-3-2019 3:47:39 PDT
Buy It Now for only: $12.09
Buy It Now | Add to watch list

 

DEPRESSION...TREATMENT John Pollitt 1965 index HC DJ ᴺ D2
$24.45
End Date: Friday Oct-11-2019 20:23:06 PDT
Buy It Now for only: $24.45
Buy It Now | Add to watch list

 

More Depression Treatment Information…